- Home
- LSTA vs PULM Comparison
LSTA vs PULM Comparison
Compare LSTA & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- PULM
- Stock Information
- Founded
- LSTA 1980
- PULM 2003
- Country
- LSTA United States
- PULM United States
- Employees
- LSTA N/A
- PULM N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- PULM Health Care
- Exchange
- LSTA Nasdaq
- PULM Nasdaq
- Market Cap
- LSTA 25.1M
- PULM 20.5M
- IPO Year
- LSTA N/A
- PULM N/A
- Fundamental
- Price
- LSTA $2.53
- PULM $4.71
- Analyst Decision
- LSTA Strong Buy
- PULM
- Analyst Count
- LSTA 2
- PULM 0
- Target Price
- LSTA $23.50
- PULM N/A
- AVG Volume (30 Days)
- LSTA 33.8K
- PULM 10.4K
- Earning Date
- LSTA 08-07-2025
- PULM 08-06-2025
- Dividend Yield
- LSTA N/A
- PULM N/A
- EPS Growth
- LSTA N/A
- PULM N/A
- EPS
- LSTA N/A
- PULM N/A
- Revenue
- LSTA $1,070,000.00
- PULM $369,000.00
- Revenue This Year
- LSTA N/A
- PULM N/A
- Revenue Next Year
- LSTA N/A
- PULM $134.88
- P/E Ratio
- LSTA N/A
- PULM N/A
- Revenue Growth
- LSTA N/A
- PULM N/A
- 52 Week Low
- LSTA $1.87
- PULM $1.78
- 52 Week High
- LSTA $4.20
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- LSTA 45.71
- PULM 32.51
- Support Level
- LSTA $2.55
- PULM $4.65
- Resistance Level
- LSTA $2.87
- PULM $5.09
- Average True Range (ATR)
- LSTA 0.20
- PULM 0.28
- MACD
- LSTA -0.02
- PULM -0.01
- Stochastic Oscillator
- LSTA 12.70
- PULM 5.38
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).